101752-05-0Relevant articles and documents
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
-
, (2008/06/13)
Substituted heteroaromatic compounds of formula (I) and in particular substituted quinolines and quinazolines, are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of cancer and psoriasis, or a salt or solvate thereof; wherein X is N or CH; Y is a group W(CH2), (CH2)W, or W, in which W is O, S(O)mwherein m is 0, 1 or 2, or NRawherein Rais hydrogen or a C1-8alkyl group; R1represents a phenyl group or a 5- or 6-membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S(O)m, wherein m is as defined above, with the provisos that the ring does not contain two adjacent O or S(O)matoms and that where the ring contains only N as heteroatom(s) the ring is C-linked to the quinazoline or quinoline ring, R1being optionally substituted by one or more R3;groups; P=0 to 3; U, R2, R3are as defined in the application.
Cephalosporin derivatives
-
, (2008/06/13)
A compound of the formula I: STR1 in which R1 is any C-3 substituent from antibacterially-active cephalosporins; R2 is any C-4 substituent from antibacterially-active cephalosporins; R3 is H, hydroxy, amino, 1-6C alkyl, 1-
